Novel monoclonal antibody reduces disease severity in psoriatic arthritis, suggesting new therapeutic potential.
Interleukin-17A (IL-17A) plays a pivotal role in the pathogenesis of psoriatic arthritis. We generated a high-affinity monoclonal antibody against IL-17A using hybridoma technology and characterized its binding kinetics, neutralization potency, and in vivo efficacy in an experimental arthritis model. The antibody demonstrated superior affinity compared to existing therapeutics and significantly reduced disease severity in treated animals. These results support the potential of this novel antibody as a therapeutic candidate.
No takes yet. Share an insight, caveat, or question.
Mozzan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: